Wisconsin Pharmacal contests Chartex' female condom approval by FDA; firms may merge.
This article was originally published in The Tan Sheet
Executive Summary
WISCONSIN PHARMACAL SEEKS WITHDRAWAL OF CHARTEX' FEMALE CONDOM FDA APPROVAL while Wisconsin Pharmacal is in discussions with Chartex about ways the two firms can collaborate in the global marketing of female condoms, Wisconsin Pharmacal said on Aug. 11. The discussions could result in a merger of the two firms, Wisconsin Pharmacal added.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning